Clinical trials: Overweight and Obesity
Healthy, Obesity
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous…
- Trial name
- NCT07693231
- Testing
- BI 3034701
- Where
- 3 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Sleep Apnea, Obstructive
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index…
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Trial name
- NCT06931028
- Testing
- IBI362
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight, Obesity
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Trial name
- NCT07523711
- Testing
- COC, Maridebart Cafraglutide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Amgen
Hyperphagia, Prader-Willi Syndrome
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.
- Trial name
- HERO (NCT06828861)
- Testing
- ARD-101
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 68 people
- Sponsor
- Aardvark Therapeutics, Inc.
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Obesity
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
The study is intended to understand the distribution of different obesity classes and obesity related diseases (diseases that present along with obesity) in patients with body mass index (BMI) ≥ 30 kg/m^2.
- Trial name
- ExplorEUEast (NCT05795166)
- Testing
- No treatment given
- Volunteers
- 1,241 people
- Sponsor
- Novo Nordisk A/S
Obesity
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
- Trial name
- NCT06886126
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight and Obesity
Policaptil Gel Retard® in Overweight and Mild Obese Subjects
This is a randomized, double blind, placebo controlled, interventional clinical study aimed at evaluating the effects of the medical device Libramed (Policaptil Gel Retard®) on the glycemic, lipid and weight profile in overweight…
- Trial name
- NCT03423368
- Testing
- Libramed
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Aboca Spa Societa' Agricola
Obesity
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Single ascending dose of HM15211 in healthy obese subjects.
- Trial name
- NCT03374241
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection.
- Trial name
- NCT07748351
- Testing
- MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4)
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety.
- Trial name
- UNISHAPE-OSA-1 (NCT07767942)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Hypertension, Insulin Resistance
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
- Conditions
- Hypertension, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00185094
- Testing
- Olmesartan medoxomil, Losartan potassium, Atenolol
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Obesity, Overweight
THE ENLIGHTEN STUDY
The primary objective of this study is to demonstrate the safety and efficacy of the Elipse Gastric Balloon System for the treatment of obese adults.
- Trial name
- NCT03261453
- Testing
- Active Elipse Device
- Where
- 12 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allurion Technologies
Obesity
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise…
- Trial name
- NCT00331175
- Testing
- Peptide YY3-36
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Trial name
- ATTAIN-1 (NCT05869903)
- Testing
- Orforglipron
- Where
- 138 sites in United States, Brazil and 8 more
- Volunteers
- 3,127 people
- Sponsor
- Eli Lilly and Company
Obesity
Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children
The purpose of this clinical trial is to examine the effects of conjugated linoleic acid (CLA) vs metformin along with an intervention program with healthy habits on body composition, weight, M value in CLAMP and clinical…
- Trial name
- NCT02063802
- Testing
- metformin, Conjugated Linoleic Acid, Healthy habits program
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited